EC1456 – Cancer
EC1456 targets a chemotherapy drug to folate receptors over expressed on cancer cells. EC1456 targets a “super-potent” chemotherapy drug called tubulysin using our second-generation guidance system.
EC1719 – Cancer
EC1669 – Anti-inflammatory
EC1669 targets a highly potent anti-folate drug to activated macrophages overexpressing folate receptors.
EC0371 – Polycystic Kidney Disease (PKD)
EC0371 is a folate-targeted, water soluble form of rapamycin that selectively inhibits mTOR activity in polycystic kidneys to reduce abnormal growth.
EC0371 is currently in preclinical development.